Anaplastic Large Cell Lymphoma, ALK-Positive Clinical Trials

16 clinical trials for Anaplastic Large Cell Lymphoma, ALK-Positive across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas — RECRUITING · PHASE1
• A Registry for People With T-cell Lymphoma — RECRUITING
• Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL — RECRUITING · PHASE2
• International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine — RECRUITING
• Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors — RECRUITING · PHASE1
• Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) — NOT_YET_RECRUITING · PHASE1
• A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma — COMPLETED · PHASE2
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms — COMPLETED · PHASE2
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma — COMPLETED · PHASE2
• Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma — COMPLETED · PHASE1
• Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma — COMPLETED
• Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas — COMPLETED · PHASE2
• Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma — WITHDRAWN · PHASE2
• Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma — WITHDRAWN · PHASE1

Refine this search